Form 4: Organon & Co. Director Reports Phantom Stock Transaction

Ramona Sequeira, a Director at Organon & Co., reported a transaction involving phantom stock units, reflecting an economic equivalent of common stock.

Summary

• Ramona Sequeira, a Director of Organon & Co., has filed a Form 4 reporting a transaction related to phantom stock units.
• The transaction, dated June 12, 2026, involved the acquisition of 17,857.143 phantom stock units.
• These phantom stock units are economically equivalent to Organon common stock on a 1-for-1 basis.
• The phantom stock units are part of the Organon Non-Employee Director Savings Plan and are payable in cash upon termination of service as a director.
• The filing also notes that holdings include phantom stock acquired through dividend reinvestment on September 11, 2025, December 11, 2025, March 12, 2026, and June 11, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine reporting of director compensation and benefit plan transactions rather than a significant strategic or financial event.

Positives

• Director Sequeira's continued participation in the company's savings plan indicates ongoing commitment.
• Dividend reinvestment in phantom stock suggests a positive outlook on future stock value by management.

Negatives

• The filing does not detail the specific cash value of the phantom stock units at the time of acquisition, only their equivalent number of shares.

Risks

• The value of the phantom stock is subject to the future performance of Organon & Co. common stock, which carries inherent market risks.
• The cash payout is contingent upon the director's termination of service, introducing a timing risk for the benefit realization.

Future Outlook

The phantom stock units are payable in cash upon termination of service, indicating a future cash outflow for the company tied to director tenure and the value of Organon's common stock at that future date.

Industry Context

StockSavvy.ai notes that the use of phantom stock units is a common executive and director compensation tool in the pharmaceutical and healthcare sectors, allowing for alignment of incentives with shareholder value without immediate dilution of common stock.

Related Party Transactions

• The transaction involves a director (Ramona Sequeira) and the company (Organon & Co.) under a non-employee director savings plan, which is a standard related party transaction disclosed in such filings.

Stakeholder Impact

• Shareholders: The phantom stock represents a future liability for the company, but its value is tied to the company's stock performance, aligning director interests with shareholders.
• Employees: This filing does not directly impact employees, but it reflects the compensation structure for the board.
• Creditors: The cash payout for phantom stock is a future obligation, but typically not significant enough to impact creditors unless the company is in severe financial distress.

Next Steps

• Ramona Sequeira will receive a cash payment for the phantom stock units upon termination of her service as a director.
• Organon & Co. will be required to make a cash settlement for these units at the time of termination.

Key Dates

Keywords

Organon & Co., OGN, Form 4, Insider Trading, Phantom Stock, Director Compensation, Securities Exchange Act, SEC Filing, Beneficial Ownership